Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study
暂无分享,去创建一个
M. Cooperberg | S. Kaplan | S. Greenfield | K. Hoffman | D. Penson | Zhiguo Zhao | T. Koyama | M. Hashibe | Chad Tang | A. Hamilton | A. Stroup | L. Paddock | M. Goodman | Li-Ching Huang | Xiao-Cheng Wu | D. Barocas | C. Wallis | B. De | D. Pasalic | Brock B. O’Neil | Brock O'Neil
[1] É. Vigneault,et al. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study. , 2021, Brachytherapy.
[2] N. Clarke,et al. Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: a national population-based study. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] M. Cooperberg,et al. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. , 2020, JAMA.
[4] A. D'Amico,et al. Combined External Beam Radiation Therapy and Brachytherapy Versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer , 2019, International Journal of Radiation Oncology*Biology*Physics.
[5] A. D'Amico,et al. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality , 2019, JAMA oncology.
[6] D. Brachman,et al. Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer , 2018, International Journal of Radiation Oncology*Biology*Physics.
[7] A. Kishan,et al. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer , 2018, JAMA.
[8] J. Tward,et al. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database , 2018, Advances in radiation oncology.
[9] W. J. Morris,et al. ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. , 2017, International Journal of Radiation Oncology, Biology, Physics.
[10] W. J. Morris,et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.
[11] A. Kishan,et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. , 2017, European urology.
[12] Ronald C. Chen,et al. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer , 2017, JAMA.
[13] David Gillatt,et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. , 2016, The New England journal of medicine.
[14] James E. Helmreich. Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis (2nd Edition) , 2016 .
[15] U. Isacsson,et al. Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes , 2015, Acta oncologica.
[16] Roma Maguire,et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Wein,et al. Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. , 2012, Health services research.
[18] Martin G Sanda,et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. , 2010, Urology.
[19] S. Kaplan,et al. Who Can Respond to Treatment?: Identifying Patient Characteristics Related to Heterogeneity of Treatment Effects , 2010, Medical care.
[20] Wadih Arap,et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.
[21] D. Lubeck,et al. Assessment of prognosis with the total illness burden index for prostate cancer , 2007, Cancer.
[22] John T. Wei,et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Bokhour,et al. Measuring Patients' Perceptions of the Outcomes of Treatment for Early Prostate Cancer , 2003, Medical care.
[24] D. Lubeck,et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. , 1996, Urology.
[25] Barbara Gandek,et al. Patient and Visit Characteristics Related to Physicians' Participatory Decision-Making Style: Results from the Medical Outcomes Study , 1995, Medical care.
[26] D L Patrick,et al. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). , 1994, American journal of preventive medicine.
[27] H. White. A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity , 1980 .
[28] John T. Wei,et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. , 2015, Urology.
[29] G. Andriole. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .
[30] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .
[31] C. Sherbourne,et al. The MOS social support survey. , 1991, Social science & medicine.
[32] P. J. Huber. The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .